Enliven Therapeutics, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Equivalents | $98.9M | $124.1M | $100.1M | $75.5M | $48.3M | $47.7M | $4.9M |
| Accounts Receivable | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — |
| Total Current Assets | $474.9M | $318.1M | $266.2M | $77.8M | $92.7M | $90.4M | $30.6M |
| Property, Plant & Equipment | $34.0K | $458.0K | $742.0K | $890.0K | $250.0K | $349.0K | $442.0K |
| Goodwill | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — |
| Total Assets | $476.2M | $325.8M | $271.9M | $83.3M | $93.6M | $90.8M | $33.3M |
| Liabilities | |||||||
| Accounts Payable | $2.2M | $1.3M | $532.0K | $3.4M | $2.4M | $2.0M | $1.7M |
| Total Current Liabilities | $16.6M | $15.9M | $25.9M | $9.7M | $7.2M | $6.2M | $4.2M |
| Long-Term Debt | — | — | — | — | — | — | — |
| Total Liabilities | $16.6M | $15.9M | $26.0M | $10.4M | $7.6M | $6.4M | $4.4M |
| Stockholders' Equity | |||||||
| Retained Earnings | $-347.2M | $-243.5M | $-154.4M | $-82.9M | $-147.5M | $-96.1M | $-54.8M |
| Total Stockholders' Equity | $459.6M | $309.8M | $245.9M | $-76.8M | $-42.9M | $84.4M | $-48.8M |